SOPH vs. WVE, IMTX, AMLX, DNTH, PRAX, COLL, SPRY, NBTX, CRON, and BCAX
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include WAVE Life Sciences (WVE), Immatics (IMTX), Amylyx Pharmaceuticals (AMLX), Dianthus Therapeutics (DNTH), Praxis Precision Medicines (PRAX), Collegium Pharmaceutical (COLL), ARS Pharmaceuticals (SPRY), Nanobiotix (NBTX), Cronos Group (CRON), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.
SOPHiA GENETICS vs. Its Competitors
SOPHiA GENETICS (NASDAQ:SOPH) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
SOPHiA GENETICS currently has a consensus price target of $8.00, suggesting a potential upside of 98.02%. WAVE Life Sciences has a consensus price target of $20.33, suggesting a potential upside of 161.02%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than SOPHiA GENETICS.
WAVE Life Sciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -40.99%. SOPHiA GENETICS's return on equity of -30.69% beat WAVE Life Sciences' return on equity.
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 24.0% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
SOPHiA GENETICS has higher earnings, but lower revenue than WAVE Life Sciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, WAVE Life Sciences had 4 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 8 mentions for WAVE Life Sciences and 4 mentions for SOPHiA GENETICS. WAVE Life Sciences' average media sentiment score of 0.56 beat SOPHiA GENETICS's score of 0.29 indicating that WAVE Life Sciences is being referred to more favorably in the news media.
SOPHiA GENETICS has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.37, suggesting that its stock price is 237% less volatile than the S&P 500.
Summary
WAVE Life Sciences beats SOPHiA GENETICS on 11 of the 16 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
This page (NASDAQ:SOPH) was last updated on 10/13/2025 by MarketBeat.com Staff
